Celephthalide C



Compound IDCDAMM00161
Common nameCelephthalide C
IUPAC name(3R,3aS)-3-[(3S)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-3a,4,5,6-tetrahydro-3H-2-benzofuran-1-one
Molecular formulaC18H28O8

Experimental data

Retention time26.9
Adduct[M+H]+
Actual mz373.186
Theoretical mz373.186
Error0.02
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0898

Identifiers and class information

Inchi keyZMZOLLLUCBNZTC-KGQRLBAUNA-N
SmilesCC(CCC1C2CCCC=C2C(=O)O1)OC3C(C(C(C(O3)CO)O)O)O
SuperclassLipids and lipid-like molecules
ClassFatty Acyls

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)10
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)372.414
Computed dipole moment(dipole)10.011
Total solvent accessible surface area (SASA)643.555
Hydrophobic component of SASA (FOSA)386.884
Hydrophilic component of SASA (FISA)223.529
Pie component of the SASA (PISA)33.142
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1159.99
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)13.2
Free energy of solvation of dipole (dip^2/V)0.0864021
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0410222
Globularity descriptor (glob)0.829627
Predicted polarizability in cubic angstroms (QPpolrz)34.164
Predicted hexadecane/gas partition coefficient (QPlogPC16)11.709
Predicted octanol/gas partition coefficient (QPlogPoct)25.212
Predicted water/gas partition coefficient (QPlogPw)19.668
Predicted octanol/water partition coefficient (QPlogPo/w)-0.454
Predicted aqueous solubility (QPlogS)-2.367
Conformation-independent predicted aqueous solubility (CIQPlogS)-2.026
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.447
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)75.193
Predicted brain/blood partition coefficient (QPlogBB)-2.204
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)30.174
Predicted skin permeability, log Kp (QPlogKp)-4.562
PM3 calculated ionization potential (IP(ev))10.204
PM3 calculated electron affinity (EA(eV))0.151
Number of likely metabolic reactions (#metab)6
Prediction of binding to human serum albumin (QPlogKhsa)-0.93
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)57.869
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)140.326
Number of nitrogen and oxygen atoms (#NandO)8
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P32320CDACytidine deaminase (by homology)T79027SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P05231IL6Interleukin-6T32578SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T79027DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P32320CDA
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T32578DI0028Anemia[ICD-11: 3A00-3A9Z]P05231IL6

Copyright © 2025